Does p53 status influence tumor response to anticancer therapies?

Anti-Cancer Drugs

Volumn 11, Issue 6, 2000, Pages 419-432

  Pirollo, Kathleen F ^a,b   Bouker, Kerrie B ^a   Chang, Esther H ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Clinical studies; Gene therapy; P53; Radiation therapy; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

CANCER; CANCER CHEMOTHERAPY; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIZATION; GENE LOSS; GENE THERAPY; HUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0033851133     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200007000-00002     Document Type: Review

References (121)

1. p53-Oriented cancer therapies: Current progress
2. Regulators and mediators of the p53 tumor suppressor
3. The p53 pathway
4. Mechanisms of p53-mediated apoptosis
5. p53 Mutations in human cancers
6. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress
7. Radiosensitivity and oxidative signalling in ataxia telangiectasia: An update
8. The cellular gatekeeper for growth and division
9. Mechanisms of p53-mediated apoptosis
10. The dual role model for p53 in maintaining genomic integrity
11. P53 status and the efficacy of cancer therapy in vivo
12. Thymocyte apoptosis induced by p53- dependent and independent pathways
13. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
14. p53 Protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
15. Mutant p53 protein associated with chemosensitivity in breast cancer specimens
16. Usefulness of p53 protein, Bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumors
17. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer
18. p53 Mutations and overexpression in locally advanced breast cancers
19. Disruption of p53 function sensitizes breast cancer mcf-7 cells to cisplatin and pentoxifylline
20. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
21. Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene
22. Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer
23. p53 Alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study
24. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas
25. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
26. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation
27. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines
28. The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy
29. P53 is required for radiation-induced apoptosis in mouse thymocytes
30. P53 mutations increase resistance to ionizing radiation
31. Transfection of rat embryo cells with mutant p53 increases the intrinsic radiation resistance
32. Transmission of in-vitro radioresistance in a cancer-prone family
33. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome
34. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity
35. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells
36. p53 Function influences the effect of fractionated radiotherapy on glioblastoma tumors
37. 1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma
38. Role of p53 mutations in the radiosensitivity status of tumor cells
39. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
40. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy
41. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value
42. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to extemal beam radiotherapy
43. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer
44. p53 Mutation and locoregional treatment failure in head and neck squamous cell carcinoma
45. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma
46. P53 expressions: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma
47. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy
48. P53 overexpression in head and neck carcinoma and radiotherapy results
49. Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients
50. Radioresistance and p53 status of T2 laryngeal carcinoma. Analysis by immunohistochemistry and denaturing gradient gel electrophoresis
51. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy
52. p53 Mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma
53. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells
54. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
55. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
56. p53, and tumor cell sensitivity to anticancer agents
57. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus
58. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck
59. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma
60. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model
61. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
62. High-efficiency gene transferand high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus
63. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblasoma cells in vitro and in vivo
64. Adenovirus-mediated p53 gene transfer inhibits grouth of human tumor cells expressing mutant p53 protein
65. Adenoviral-mediated p53 tumor suppressor gene therapy ofhumanovariancarcinoma
66. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts
67. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer
68. P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy
69. 1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy
70. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
71. Spatial and temporal control of gene therapy using ionizing radiation
72. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
73. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
74. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
75. 1 checkpoint-competent cells
76. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins
77. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
78. Ligand-directed retroviral targeting of human breast cancer cells
79. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes
80. Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway
81. Targeting DNA to cells with basic fibroblast growth factor (FGF2)
82. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor
83. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
84. Targeted, non-viral gene delivery for cancer gene therapy
85. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro
86. Systemic p53 gene therapy in combination with radiation results in human tumor regression
87. Transferrin-liposome-mediated systematic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts
88. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
89. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents
90. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
91. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
92. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?
93. p53 Expression and the result of adjuvant therapy of breast cancer
94. p53 Mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas
95. The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells
96. p53 Protein accumulation as a prognostic marker of preoperative radiotherapy and/or chemotherapy in advanced squamous cell esophageal carcinoma - Preliminary report
97. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma
98. Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy
99. Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas
100. p53 Mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons
101. 1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells
102. Combined radiation adn p53 gene therapy of malignant glioma cells
103. p53 Mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines
104. Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma
105. Transformation and radiosensitivity of human diploid skin fibroblasts transfected with SV40 T-antigen mutants defective in RB and P53 binding domains
106. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras
107. The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma
108. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma
109. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: A report of randomized trial RTOG 87-04. Radiation therapy oncology group
110. Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy
111. p53 Mutations predict non-small cell lung carcinoma response to radiotherapy
112. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy
113. Manganese superoxide dismutase expression correlates with p53 status and local recurrence of cervical carcinoma treated with radiation therapy
114. bcl-2 Immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma
115. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma
116. p53 Mutation as a prognostic marker in advanced laryngeal carcinoma. Department of veterans affairs laryngeal cancer cooperative study group
117. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer
118. Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma
119. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines